Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDIV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Small Cell Lung Carcinoma 5Sarcoma, Ewing 3Sarcoma 3Endometrial Neoplasms 3Neoplasms 2Stomach Neoplasms 1SCLC, Extensive Stage 1Recurrence 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Mesothelioma 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Trastuzumab 62Paclitaxel 57Cyclophosphamide 44pembrolizumab 34Fulvestrant 34Capecitabine 29Carboplatin 26Docetaxel 23Letrozole 22Doxorubicin 19palbociclib 16abemaciclib 16pertuzumab 15durvalumab 14Filgrastim 13Everolimus 13ribociclib 12Lapatinib 12Gemcitabine 12exemestane 11eribulin 11Vinorelbine 11Albumin-Bound Paclitaxel 11Bevacizumab 10trastuzumab deruxtecan 9neratinib 9fludarabine 9Taxes 9Radiotherapy 9Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms × PM 01183 × Clear all
NCT02684318 2017-06-22

Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors

Poveda, Andrés, M.D.

Phase 1/2 Unknown
100 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡